A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion.

ABSTRACT: Recent advances in stroke reperfusion therapies have led to remarkable improvement in clinical outcomes, but many patients remain severely disabled, due in part to the lack of effective neuroprotective strategies. In this review, we show that 95% of published preclinical studies on "neuroprotectants" (1990-2018) reported positive outcomes in animal models of ischemic stroke, while none translated to successful Phase III trials. There are many complex reasons for this failure in translational research, including that the majority of clinical trials did not test early delivery of neuroprotectants in combination with successful reperfusion. In contrast to the clinical trials, >80% of recent preclinical studies examined the neuroprotectant in animal models of transient ischemia with complete r

SUBMITTER: Shi L 

PROVIDER: S-EPMC6282224 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature